Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 557 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance MOST POPULAR EMA Recommends Extension of Indications for Lorlatinib December 20, 2021 Bus Driver Wears Different Costume Each Day To Make Kids Smile... January 27, 2022 How Joining a Clinical Trial Helped Me Find Hope While Living... December 5, 2023 Less Frequent Mammographic Surveillance Non-inferior Compared with Annual Mammograms After Diagnosis... February 18, 2025 Load more HOT NEWS Cancer Research UK’s Race for Life celebrates its 30th year by... Όροι χρήσης και προϋποθέσεις Spending Review 2020 – Steps in the right direction, but opportunities... First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma
